NEUROPHTH THERAPEUTICS
Neurophth is China's first gene therapy company for ophthalmic diseases. As a clinical-stage company, Neurophth is dedicated to discovering and developing gene therapies for patients suffering from blindness and other eye diseases globally.
NEUROPHTH THERAPEUTICS
Industry:
Biotechnology Life Science
Founded:
2016-07-01
Address:
Wuhan, Hubei, China
Country:
China
Website Url:
http://www.neurophth.com
Total Employee:
251+
Status:
Active
Contact:
+027-65524119
Total Funding:
140.3 M USD
Technology used in webpage:
DNS.COM
Similar Organizations
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Employees Featured
Zhang Xin Chief Operating Officer & Chief Medical Officer @ Neurophth Therapeutics
Chief Operating Officer & Chief Medical Officer
Li Qiutang Chief Scientific Officer @ Neurophth Therapeutics
Chief Scientific Officer
Dr. Bose Kalampanayil Chief Technology Officer @ Neurophth Therapeutics
Chief Technology Officer
Li Bin Founder & Chairman @ Neurophth Therapeutics
Founder & Chairman
Su Zhang Chief Financial Officer @ Neurophth Therapeutics
Chief Financial Officer
2021-11-01
Dr. Yingming Lu Chief Executive Officer @ Neurophth Therapeutics
Chief Executive Officer
Guo Xiaoning Chief Medical Officer @ Neurophth Therapeutics
Chief Medical Officer
2022-06-01
Dr Xiao Su Co-founder, Chief Technology Operation Officer @ Neurophth Therapeutics
Co-founder, Chief Technology Operation Officer
Founder
Investors List
Sunshine Insurance Group
Sunshine Insurance Group investment in Series C - Neurophth Therapeutics
CMB International Capital Corporation
CMB International Capital Corporation investment in Series C - Neurophth Therapeutics
Sequoia Capital China
Sequoia Capital China investment in Series C - Neurophth Therapeutics
CMG-SDIC Capital Management
CMG-SDIC Capital Management investment in Series C - Neurophth Therapeutics
Northern Light Venture Capital
Northern Light Venture Capital investment in Series B - Neurophth Therapeutics
InnoVision Capital
InnoVision Capital investment in Series B - Neurophth Therapeutics
Harvest Capital
Harvest Capital investment in Series B - Neurophth Therapeutics
Guofang Capital
Guofang Capital investment in Series B - Neurophth Therapeutics
Sequoia Capital China
Sequoia Capital China investment in Series B - Neurophth Therapeutics
Grand Mount Capital
Grand Mount Capital investment in Series B - Neurophth Therapeutics
Key Employee Changes
Official Site Inspections
http://www.neurophth.com
- Host name: 8.141.8.88
- IP address: 8.141.8.88
- Location: China
- Latitude: 34.7725
- Longitude: 113.7266
- Timezone: Asia/Shanghai
More informations about "Neurophth Therapeutics"
Neurophth Therapeutics - Crunchbase Company Profile & Funding
Organization. Neurophth Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... As a clinical-stage company, Neurophth …See details»
neurophth - 纽福斯生物
纽福斯生物,纽福斯,眼科基因治疗,neurophthSee details»
Neurophth biological tech
Neurophth and Sinopharm Holding Collaborate to Successfully Complete the Winter Transportation Verification of Newvision®, Pioneering the Commercial Transportation and …See details»
Neurophth Therapeutics / 纽福斯生物科技有限公司 | LinkedIn
Day 3@Bioprocessing Summit Europe Dr. Su Xiao from our strategic collaborator Neurophth Therapeutics / 纽福斯生物科技有限公司 presented an amazing talk titled “a Novel 3-plasmid ...See details»
Neurophth - Products, Competitors, Financials, Employees, …
Neurophth is a gene therapy company that focuses on ophthalmic diseases within the biotechnology sector. Use the CB Insights Platform to explore Neurophth's full profile. …See details»
Wuhan Neurophth Biotechnology Co., Ltd - Drug pipelines, …
Jun 7, 2024 Explore Wuhan Neurophth Biotechnology Co., Ltd with its drug pipeline, therapeutic area, technology platform, 5 clinical trials, 12 news, Disease Domain:Endocrinology and …See details»
NEWS - neurophth.com
Oct 30, 2023 Recently, the results of the 2023 "Top 20 High-tech High-growth Enterprises in Optics Valley" and "Optics Valley Rising Stars" list, which was jointly hosted by Deloitte China …See details»
Neurophth Therapeutics (武汉纽福斯生物科技有限公司) - 药物管 …
了解Neurophth Therapeutics (武汉纽福斯生物科技有限公司)公司的药物管线，治疗领域，技术平台，以及它的6项临床试验, 20篇新闻，疾病领域:内分泌与代谢疾病，神经系统疾病，感染， …See details»
Neurophth 纽福斯
Neurophth成立的目的是开发眼科疾病的基因疗法。 2017 在2011-2012年IIT取得了令人鼓舞的结果之后，李斌博士的团队在2017-2018年进行了第二次IIT，将继续包括159名患者这些研究表明，基因治疗具有良好的耐受性，可以为患者带来 …See details»
CN112029773 - Drug Targets, Indications, Patents - Synapse
CN112029773, Initially developed by Neurophth Therapeutics, Now, its global highest R&D status is Discovery, Therapeutic Areas: Eye Diseases, Active Indication: Eye Diseases, Active Org.: …See details»
Neurophth Therapeutics' Treatment of Leber's …
Jan 25, 2022 Ms. Yiyuan Chen, Head of Global Regulatory Affairs of Neurophth, commented, "We are very pleased to receive EMA's orphan drug designation, which is another good news following the recent US IND ...See details»
公司动态 - neurophth
Feb 22, 2023 公司管线还包括常染色体显性视神经萎缩，光学神经保护，血管视网膜病变等临床前候选药物。纽福斯已启动苏州工厂的内部生产扩能，以支持未来的商业需求。要了解更多关 …See details»
OMIX
Mar 31, 2024 MA MING (chaoming.ma@neurophth.com) Organization: Wuhan Neuropohth Biotechnology Limited Company: Submission Date: 2022-04-01: 2 Files & Download. HTTP …See details»
全球唯一在研疗法！纽福斯第二款眼科基因治疗药物NFS-02获批国 …
⌈ByDrug医药新闻摘要⌋ 2023-04-17 08:00，纽福斯生物：2023年4月17日，中国专注于眼科疾病的基因治疗领导者纽福斯生物科技有限公司（下称“纽福斯”）宣布 公司第二款基因治疗药物NFS …See details»
Neurophth Therapeutics' Treatment of Leber's Hereditary Optic ...
NEWARK, Del., Sept. 24, 2020 /PRNewswire/ -- Neurophth Therapeutics, Inc., (hereinafter referred to as "Neurophth") today announced that its leading candidate, NR082 (rAAV2-ND4, …See details»
Neurophth Announces Completion of Patient Enrollment for …
Feb 19, 2024 WUHAN, China and SAN DIEGO, Feb. 19, 2024 /PRNewswire/ -- Neurophth Therapeutics, Inc. ("Neurophth") announced today that the last patient has been enrolled in …See details»
纽福斯眼科基因治疗药物NR082中国III期临床试验完成首例患者入 …
⌈ByDrug医药新闻摘要⌋ 2022-09-27 08:30，纽福斯生物：2022年9月27日，中国专注于眼科疾病的体内基因治疗领导者纽福斯生物科技有限公司（下称“纽福斯”）宣布公司核心产品NR082眼用 …See details»
Neurophth gets Australian approval for ophthalmic gene therapy
Sep 6, 2023 According to news release, Neurophth is an in-vivo gene therapy company for ophthalmic diseases with subsidiaries in China (Wuhan, Shanghai and Suzhou) and the …See details»
NEWS - neurophth.com
Neurophth’s New Brand, New Standard, and New Achievement Highlighted at World Health Expo Source: Release Date: 2024-05-06 The 6th World Health Expo, hosted by the National Health …See details»
公司动态 - neurophth
2022年9月27日，中国专注于眼科疾病的体内基因治疗领导者纽福斯生物科技有限公司（下称“纽福斯”）宣布公司核心产品nr082眼用注射液（raav2-nd4, nfs-01），用于治疗nd4突变引起 …See details»